One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

Deborah Morosini net worth and biography

Deborah Morosini Biography and Net Worth

EVP of Prelude Therapeutics

Deborah Morosini, M.D., M.S.W. joined Prelude Therapeutics in 2020 and currently serves as Executive Vice President and Chief of Clinical Affairs. She brings to Prelude extensive expertise in oncology drug development, clinical genomics, and philanthropic activism. She previously served as Vice President of Clinical Affairs and Patient Engagement (Chief Patient Officer) at Loxo Oncology, where she built and led patient engagement and enrollment strategy, medical affairs, and patient advocacy. Dr. Morosini played a key role in the launch of Vitrakvi® (larotrectinib) via a co-promote partnership with Bayer, and conducted launch preparations for LOXO-292, a RET inhibitor for lung and thyroid cancer. Prior to Loxo, she was an early team member at Foundation Medicine, where she developed a niche specialty in the genomics of adolescent and young adult cancer. Before joining Foundation Medicine, she founded and led the molecular pathology group at AstraZeneca Pharmaceuticals, where she helped develop and implement biomarker strategies for biomarker-driven trials. Prior to AstraZeneca, Dr. Morosini served as Director of Pathology for Ardais, a clinical genomics biotechnology company. She has been featured as a spokesperson for numerous non-profit and government events in oncology and has provided expert commentary for national broadcast media. She has served on numerous national oncology non-profit boards, and currently serves on the Board of Directors for ClinWiki and the SAB for Target Cancer and Upstage Lung Cancer. Dr. Morosini earned her B.A. in English from Mount Holyoke College, her M.S.W. from NYU Graduate School of Social Work, and her M.D. from Boston University School of Medicine. She completed a pathology residency at Boston Medical Center.

How do I contact Deborah Morosini?: The corporate mailing address for Dr. Morosini and other Prelude Therapeutics executives is , , . Prelude Therapeutics can also be reached via phone at 302-467-1280 and via email at [email protected]. Learn More on Deborah Morosini's contact information.
Has Deborah Morosini been buying or selling shares of Prelude Therapeutics?: Deborah Morosini has not been actively trading shares of Prelude Therapeutics in the last ninety days. Most recently, Deborah Morosini sold 28,751 shares of the business's stock in a transaction on Tuesday, November 16th. The shares were sold at an average price of $15.88, for a transaction totalling $456,565.88. Learn More on Deborah Morosini's trading history.
Who are Prelude Therapeutics' active insiders?: Prelude Therapeutics' insider roster includes Andrew Combs (EVP), David Mauro (Insider), Deborah Morosini (EVP), Christopher Pierce (EVP), Brian Piper (CFO), and Peggy Scherle (Insider). Learn More on Prelude Therapeutics' active insiders.
Are insiders buying or selling shares of Prelude Therapeutics?: In the last year, Prelude Therapeutics insiders bought shares 2 times. They purchased a total of 870,565 shares worth more than $5,005,008.75. The most recent insider tranaction occured on May, 24th when CEO Krishna Vaddi bought 1,000 shares worth more than $5,010.00. Insiders at Prelude Therapeutics own 79.5% of the company. Learn More about insider trades at Prelude Therapeutics.
Information on this page was last updated on 5/24/2023.

Deborah Morosini Insider Trading History at Prelude Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/16/2021	Sell	28,751	$15.88	$456,565.88

Deborah Morosini Buying and Selling Activity at Prelude Therapeutics

Prelude Therapeutics Company Overview

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Today's Range

Now: $3.72

$3.45

$3.86

50 Day Range

MA: $4.41

$3.06

$5.63

2 Week Range

Now: $3.72

$1.66

$6.89

Volume

57,895 shs

Average Volume

67,504 shs

Market Capitalization

$204.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51

Strange new buyer driving up gold

From Stansberry Research | Ad